参考文献
［1］Foundation N K.KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation,2007,49(2):S12-154.
［2］Tuttle,Katherine R,Bakris G L,BIOUS' R Wet al.Diabetic kidney disease: a report from an ADA Consensus Conference[J].Diabetes care,2014,37(10):2864-2883.
［3］中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南（2021年版）[J].中华糖尿病杂志，2021，13（8）：762-784.
［4］Anders,HJ.,Huber,T.B.,Isermann,B.et al.CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease[J].Nat Rev Nephrol,2018,14:361-377.
［5］American Diabetes Association; 11.Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020[J].Diabetes Care,2020,43(1): S135-S151.
［6］Ps A,Ip A,Ps A,et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas,9 th edition[J].Diabetes Research and Clinical Practice,2019,157:107843.
［7］Afkarian M,Zelnick L R,Hall Y N,et al.Clinical Manifestations of Kidney Disease Among US Adults With Diabetes,1988-2014[J].Jama,2016,316(6):602-610.
［8］Zhang L,Fang W,Wang L,et al.Prevalence of chronic kidney disease in China: a cross-sectional survey[J].Lancet,2012,380(9818):214-214.
［9］Guo K,Zhang L,Zhao F,et al.Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes: Cross-sectional study[J].Journal of Diabetes & Its Complications,2016:803-810.
［10］Eugenia E,Irene A,Meritxell I,et al.Renal Biopsy in Type 2 Diabetic Patients[J].Journal of Clinical Medicine,2015,4(5):998-1009.
［11］Wang K,Hu J,Luo T,et al.Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.[J].Kidney & Blood Pressure Research,2018:768-779.
［12］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021，13（4）：315-409.
［13］Shen X,Zhang Z,Zhang X,et al.Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials[J].Lipids in Health and Disease,2016,15(1):179.
［14］Ruta L M,Magliano D J,Lemesurier R,et al.Prevalence of diabetic retinopathy in Type2 diabetes in developing and developed countries[J].Diabetic Medicine,2013,30(4):387-398.
［15］Zhen L T,Tham Y C,Yu M,et al.Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis[J].Ophthalmology,2021,128(11):1580-1591.
［16］Chen-Wei Pan,Shan Wang,Deng-Juan Qian,Cailian Xu & E Song (2017)Prevalence,Awareness,and Risk Factors of Diabetic Retinopathy among Adults with Known Type 2 Diabetes Mellitus in an Urban Community in China[J].Ophthalmic Epidemiology,2017,24(3): 188-194.
［17］Fraxellaxel C J,Adelman R A,Bailey S T,et al.Diabetic Retinopathy Preferred Practice Pattern[J].Ophthalmology,2019,127(1):66-145.
［18］Kilpatrick,E.S.,Rigby,A.S.,Atkin,S.L.and Frier,B.M.(2012),Does severe hypoglycemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database[J].Diabetic Medicine: A Journal of the British Diabetic Association,2012,29(9): 1195-1198.
［19］Benefits of renin-angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control.[J].Current Medical Literature Diabetes,2011,34(8):1838-1842.
［20］Chaturvedi N,Porta M,Klein R,et al.Effect of candesartan on prevention(DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized,placebo-controlled trials[J].Lancet (London,England),2008,372(9647):1394-1402.
［21］Fox Y,George M,Svensson A,et al.Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebocontrolled trial[J].Lancet,2008,372(9647):1365-1393.
［22］Noonan J E,Jenkins A J,Ma J X,et al.An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular endpoints in patients with diabetes[J].Diabetes,2013,62(12):3968-3975.
［23］Berghoffrhoff K,Clar C,Richter B.Aspirin in diabetic retinopathy: A systematic review[J].Endocrinology & Metabolism Clinics of North America,2002,31(3):779-793.
［24］邓辉，金明，苑维，等.复方丹参滴丸治疗早期糖尿病视网膜病变的临床观察[J].中国中医眼科杂志，2005，15（2）：72-74.
［25］叶晓峰，徐格致.复方血栓通胶囊对糖尿病大鼠视网膜氧化应激损伤保护作用的观察[J].中华眼底病杂志，2010，26（002）：176-178.(https://www.daowen.com)
［26］Shabeeb D,Najafi M,Hasanzadeh G,et al.Electrophysiological measurements of diabetic peripheral neuropathy: a systematic review[J].Diabetes & Metabolic Syndrome Clinical Research & Reviews,2018，12(4):591-600.
［27］Callaghan,B.C.,Gao,L.,Li,Y.,Zhou,et al.Diabetes and obesity are the main metabolic drivers of peripheral neuropathy[J].Ann Clin Transl Neurol,2018,5(4): 397-405.
［28］Callaghan BC,Xia R,Reynolds E,et al.Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population[J].Jama Neurology,2016,73(12):1468-1476.
［29］Calcutt N A.Diabetic neuropathy and neuropathic pain: A (con) fusion of pathogenic mechanisms?[J].Pain,2020,161(1): S65-S86.
［30］Rodica Pop-Busui,Andrew J.M.Boulton,Eva L.Feldman,Vera Bril,Roy Freeman,Riyaz A.Malik,Jay M.Sosenko,Dan Ziegler; Diabetic Neuropathy: A Position Statement by the American Diabetes Association[J].Diabetes Care,2017,40 (1): 136-154.
［31］Sloan,G.,Selvarajah,D.& Tesfaye,S.Pathogenesis,diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy[J].Nat Rev Endocrinol,2021,17(7),400-420.
［32］Devigili G,Cazzato D ,Lauria G .Clinical diagnosis and management of small fiber neuropathy: an update on best practice[J].Expert Review of Neurotherapeutics,2020,20(9): 967-980.
［33］Spallone V.Update on the Impact,Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined,What Is New,and What Is Unmet[J].Diabetes & metabolism journal,2019,43(1):3-30.
［34］Yun,JS.,Park,YM.,Cha,SA.,et al.Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes.[J].Cardiovascular Diabetology,2018,17(1):109-.
［35］Mohit Kumar,Adam Chapman,Saad Javed,et al.The Investigation and Treatment of Diabetic Gastroparesis[J],Clinical Therapeutics,2018,40(6):850-861.
［36］American Diabetes Association Professional Practice Committee; 2.Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022[J].Diabetes Care,2022,45(1): S17-S38.
［37］Kempler P,Amarenco G,Freeman R,et al.Management strategies for gastrointestinal,erectile,bladder,and sudomotor dysfunction in patients with diabetes[J].Diabetes/Metabolism Research and Reviews,2011,27(7):665-677.
［38］Xin H,Li S,Yang G,et al.Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis[J].Plos One,2014,9(2):e87096.
［39］Bai-Bing Y,Zhi-Wei H,Zheng Z,et al.Epalrestat,an Aldose Reductase Inhibitor,Restores Erectile Function in Streptozocin-induced Diabetic Rats[J].International Journal of Impotence Research,2019,31(2):97-104.
［40］Sheyu L,Qianrui L,Yun L,et al.Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathic Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].Plos One,2015,10(3):e0139292.
［41］徐莉莉.冠心病合并2型糖尿病患者冠脉介入护理进展[J].中国城乡企业卫生，2021，36（8）：47-49.
［42］M Veglio,G Bruno,M Borra,et al.Prevalence of increased qt interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease:a population-based cohort[J].Journal of Internal Medicine,2002,251(4): 317-324.
［43］Chin M K,Tai ES.Trends in the incidence and mortality of coronary heart disease in asian pacific region: the singapore experience[J].Journal of Atherosclerosis and Thrombosis,2014,21(1): S2-8.
［44］Turin TC,Okamura T,Rumana N,et al.Diabetes and lifetime risk of coronary heart disease[J].Primary Care Diabetes,2017,11(5): 461-466.
［45］Zhang P,Lu J,Jing Y,et al.Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis[J].Annals of Medicine,2017,49(2): 106-116.
［46］Wang A,Xu Z,Mu Y,et al.Clinical characteristics and medical costs in patients with diabetic amputation and nondiabetic patients with nonacute amputation in central urban hospitals in china[J].The International Journal of Lower Extremity Wounds,2014,13(1): 17-21.
［47］Jiang Y,Ran X,Jia L,et al.Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in china[J].The International Journal of Lower Extremity Wounds,2015,14(1): 19-27.
［48］Xu Z,Ran X.Diabetic foot care in china: challenges and strategy[J].The Lancet.Diabetes & Endocrinology,2016,4(4): 297-298.
（林安华、盛霞、张钰英）